Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPATHY trial of empagliflozin and dapagliflozin in hospitalized acute decompensated heart failure
2020-003497-48Phase 3Active
- Sponsor
- Medical University of Warsaw
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin and dapagliflozin in heart failure (HF) (3 arms), sponsored by Medical University of Warsaw. Primary endpoint: Composite primary endpoint. Started Sep 2021; status: active.
02
Drugs
empagliflozindapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2020-003497-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003497-48.